A CXCR4 antagonist leads to tumor suppression by activation of immune cells in a leukemia-induced microenvironment

Han,A-Reum; Lee,Ji  Yoon; Kim,Hee-Je; Min,Woo-Sung; Park,Gyeongsin; Kim,Se-Hoon

doi:10.3892/or.2015.4297

A CXCR4 antagonist leads to tumor suppression by activation of immune cells in a leukemia-induced microenvironment

Authors:
- A-Reum Han
- Ji Yoon Lee
- Hee-Je Kim
- Woo-Sung Min
- Gyeongsin Park
- Se-Hoon Kim
View Affiliations

Affiliations: Cancer Research Institute, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea, Department of Hematology, Catholic Blood and Marrow Transplantation Center, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
Published online on: September 21, 2015 https://doi.org/10.3892/or.2015.4297
Pages: 2880-2888

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The bone marrow microenvironment (BMM) provides a protective niche that supports growth and survival of normal and leukemic hematopoietic stem cells. The SDF-1/CXCR4 interaction is critical for regulation of homing to and retention of hematopoietic cells in the bone marrow (BM), which leads to increased chemoresistance. SDF-1/CXCR4 plays pivotal roles in cross-interactions between blasts and the BMM to prevent retention and mobilization of leukemic cells, as well as in normal hematopoiesis including the development of immune cells. We show that the CXCR4 antagonist, plerixafor, decreased the level of CXCR4 expression and inhibited SDF-1-induced migration of leukemic cells. Further, the inhibition of the interaction between leukemic cells and the BMM by the plerixafor enhanced cytotoxic activity of immune cells as a result of increased susceptibility of leukemic cells to chemotherapeutic agents such as cytosine arabinoside (Ara-C) in a mouse model of acute myeloid leukemia (AML), suggesting biological effects of the BMM through immune cell activation. Because alterations in the BMM promote retention and survival of leukemic cells, targeting the niche is regarded as an advanced strategy to eradicate drug-resistant leukemic blasts. This study demonstrates that the effects of CXCR4 inhibition on blast suppression and immune cell function in the tumor microenvironment and chemotherapy with plerixafor represents an advanced therapeutic strategy of targeting the leukemic niche.

View Figures

View References

1	Löwenberg B, Downing JR and Burnett A: Acute myeloid leukemia. N Engl J Med. 341:1051–1062. 1999. View Article : Google Scholar : PubMed/NCBI
2	Liesveld JL, Bechelli J, Rosell K, Lu C, Bridger G, Phillips G II and Abboud CN: Effects of AMD3100 on transmigration and survival of acute myelogenous leukemia cells. Leuk Res. 31:1553–1563. 2007. View Article : Google Scholar : PubMed/NCBI
3	Lane SW, Wang YJ, Lo Celso C, Ragu C, Bullinger L, Sykes SM, Ferraro F, Shterental S, Lin CP, Gilliland DG, et al: Differential niche and Wnt requirements during acute myeloid leukemia progression. Blood. 118:2849–2856. 2011. View Article : Google Scholar : PubMed/NCBI
4	Krause DS, Fulzele K, Catic A, Sun CC, Dombkowski D, Hurley MP, Lezeau S, Attar E, Wu JY, Lin HY, et al: Differential regulation of myeloid leukemias by the bone marrow microenvironment. Nat Med. 19:1513–1517. 2013. View Article : Google Scholar : PubMed/NCBI
5	Moshaver B, van der Pol MA, Westra AH, Ossenkoppele GJ, Zweegman S and Schuurhuis GJ: Chemotherapeutic treatment of bone marrow stromal cells strongly affects their protective effect on acute myeloid leukemia cell survival. Leuk Lymphoma. 49:134–148. 2008. View Article : Google Scholar
6	Konopleva M, Konoplev S, Hu W, Zaritskey AY, Afanasiev BV and Andreeff M: Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins. Leukemia. 16:1713–1724. 2002. View Article : Google Scholar : PubMed/NCBI
7	Mercier FE, Ragu C and Scadden DT: The bone marrow at the crossroads of blood and immunity. Nat Rev Immunol. 12:49–60. 2012. View Article : Google Scholar
8	Peled A and Tavor S: Role of CXCR4 in the pathogenesis of acute myeloid leukemia. Theranostics. 3:34–39. 2013. View Article : Google Scholar : PubMed/NCBI
9	Tokoyoda K, Egawa T, Sugiyama T, Choi BI and Nagasawa T: Cellular niches controlling B lymphocyte behavior within bone marrow during development. Immunity. 20:707–718. 2004. View Article : Google Scholar : PubMed/NCBI
10	Foudi A, Jarrier P, Zhang Y, Wittner M, Geay JF, Lecluse Y, Nagasawa T, Vainchenker W and Louache F: Reduced retention of radioprotective hematopoietic cells within the bone marrow microenvironment in CXCR4^−/− chimeric mice. Blood. 107:2243–2251. 2006. View Article : Google Scholar
11	Fricker SP, Anastassov V, Cox J, Darkes MC, Grujic O, Idzan SR, Labrecque J, Lau G, Mosi RM, Nelson KL, et al: Characterization of the molecular pharmacology of AMD3100: A specific antagonist of the G-protein coupled chemokine receptor, CXCR4. Biochem Pharmacol. 72:588–596. 2006. View Article : Google Scholar : PubMed/NCBI
12	Burger JA and Peled A: CXCR4 antagonists: Targeting the microenvironment in leukemia and other cancers. Leukemia. 23:43–52. 2009. View Article : Google Scholar
13	Zhang Y, Patel S, Abdelouahab H, Wittner M, Willekens C, Shen S, Betems A, Joulin V, Opolon P, Bawa O, et al: CXCR4 inhibitors selectively eliminate CXCR4-expressing human acute myeloid leukemia cells in NOG mouse model. Cell Death Dis. 3:e3962012. View Article : Google Scholar : PubMed/NCBI
14	Zeng Z, Shi YX, Samudio IJ, Wang RY, Ling X, Frolova O, Levis M, Rubin JB, Negrin RR, Estey EH, et al: Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood. 113:6215–6224. 2009. View Article : Google Scholar :
15	Sison EA, McIntyre E, Magoon D and Brown P: Dynamic chemotherapy-induced upregulation of CXCR4 expression: A mechanism of therapeutic resistance in pediatric AML. Mol Cancer Res. 11:1004–1016. 2013. View Article : Google Scholar : PubMed/NCBI
16	Nervi B, Ramirez P, Rettig MP, Uy GL, Holt MS, Ritchey JK, Prior JL, Piwnica-Worms D, Bridger G, Ley TJ, et al: Chemo-sensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood. 113:6206–6214. 2009. View Article : Google Scholar :
17	Lee JY, Park S, Min WS and Kim HJ: Restoration of natural killer cell cytotoxicity by VEGFR-3 inhibition in myelogenous leukemia. Cancer Lett. 354:281–289. 2014. View Article : Google Scholar : PubMed/NCBI
18	Kremer KN, Peterson KL, Schneider PA, Meng XW, Dai H, Hess AD, Smith BD, Rodriguez-Ramirez C, Karp JE, Kaufmann SH, et al: CXCR4 chemokine receptor signaling induces apoptosis in acute myeloid leukemia cells via regulation of the Bcl-2 family members Bcl-XL, Noxa, and Bak. J Biol Chem. 288:22899–22914. 2013. View Article : Google Scholar : PubMed/NCBI
19	Mannelli F, Cutini I, Gianfaldoni G, Bencini S, Scappini B, Pancani F, Ponziani V, Bonetti MI, Biagiotti C, Longo G, et al: CXCR4 expression accounts for clinical phenotype and outcome in acute myeloid leukemia. Cytometry B Clin Cytom. 86:340–349. 2014. View Article : Google Scholar : PubMed/NCBI
20	Müller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, et al: Involvement of chemokine receptors in breast cancer metastasis. Nature. 410:50–56. 2001. View Article : Google Scholar : PubMed/NCBI
21	de Oliveira KB, Guembarovski RL, Guembarovski AM, da Silva do Amaral Herrera AC, Sobrinho WJ, Ariza CB and Watanabe MA: CXCL12, CXCR4 and IFNγ genes expression: Implications for proinflammatory microenvironment of breast cancer. Clin Exp Med. 13:211–219. 2013. View Article : Google Scholar
22	Meads MB, Hazlehurst LA and Dalton WS: The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res. 14:2519–2526. 2008. View Article : Google Scholar : PubMed/NCBI
23	Kopp HG, Avecilla ST, Hooper AT and Rafii S: The bone marrow vascular niche: Home of HSC differentiation and mobilization. Physiology (Bethesda). 20:349–356. 2005. View Article : Google Scholar
24	Psaila B, Lyden D and Roberts I: Megakaryocytes, malignancy and bone marrow vascular niches. J Thromb Haemost. 10:177–188. 2012. View Article : Google Scholar :
25	Yin T and Li L: The stem cell niches in bone. J Clin Invest. 116:1195–1201. 2006. View Article : Google Scholar : PubMed/NCBI
26	Balabanian K, Brotin E, Biajoux V, Bouchet-Delbos L, Lainey E, Fenneteau O, Bonnet D, Fiette L, Emilie D and Bachelerie F: Proper desensitization of CXCR4 is required for lymphocyte development and peripheral compartmentalization in mice. Blood. 119:5722–5730. 2012. View Article : Google Scholar : PubMed/NCBI